ARS Pharmaceuticals, Inc.
SPRY · XNASCIK 1671858fmd_16T1Z5BVGBNB89CMG5B8S6RBJCManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | 6 | 1 | 0 | 89 | 84 |
| Net interest income | (0) | 0 | – | – | – | – |
| Cost of revenue | – | – | – | 0 | – | – |
| Realized investment gains (losses) | – | 0 | (0) | 0 | – | – |
| Gross profit | – | – | – | 0 | – | – |
| Research and development | 25 | 20 | 18 | 20 | 20 | 13 |
| Selling, general and administrative | – | – | 1 | 47 | 72 | 230 |
| Total operating expenses | 33 | 25 | 37 | 68 | 92 | 264 |
| Operating income | (33) | (19) | (36) | (68) | (3) | (179) |
| Other non-operating income (expense) | – | (1) | 1 | 13 | 11 | 8 |
| Income before taxes | – | – | – | (54) | 8 | (171) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | (0) |
| Net income from continuing operations | – | – | – | (54) | 8 | (171) |
| Net income | (33) | (20) | (35) | (54) | 8 | (171) |